Márquez-Contreras Emilio, Martell-Carlos Nieves, Gil-Guillén Vincente, De La Figuera-Von Wichmann Mariano, Sanchez-López Eugenio, Márquez-Rivero Sara, Gil-Gil Ines, Hermida-Campa Enrique
a La Orden Health Center , Huelva , Spain.
b San Carlos Hospital , Madrid , Spain.
Curr Med Res Opin. 2016 Dec;32(12):2013-2020. doi: 10.1080/03007995.2016.1227311. Epub 2016 Sep 4.
To assess compliance with treatment with rivaroxaban in patients with non-valvular atrial fibrillation.
Prospective, longitudinal, multicenter study, developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by using electronic monitors (MEMSs) that use a digital record in the form of a microchip in the lid of the drug container that automatically controls its opening and registers the time and date of the opening. We calculated the average compliance percentage (CP), global and daily compliance. We considered compliance to be when CP was 80-100%.
Three hundred and seventy patients ended the study (mean age 75.19, SD: 7.5 years). Global compliance was 84.1% (CI = 79.21-88.99%) and 80.3% (CI = 74.98-85.62%) after 6 and 12 months respectively. Daily compliance was 83.5% (CI = 78.53-88.57%) and 80% (CI = 74.65-85.35%) at 6 and 12 months. Significant differences in the CP between 6 and 12 months were observed. Global CP was 90.77% after 6 months and 89.65% at the end of the study. Daily CP was 90.14% and 87.66% at 6 and 12 months. There were significant CP differences between 6 and 12 months. Non-compliance was associated with a higher number of concomitant diseases, number of drugs taken and weight.
The percentage of compliance with rivaroxaban was high. A profile of variables that need to be modified in current medical practice, associated with non-compliance, was detected.
评估非瓣膜性心房颤动患者对利伐沙班治疗的依从性。
在160家西班牙初级或专科护理中心开展的前瞻性、纵向、多中心研究。我们纳入了412例接受利伐沙班治疗以预防中风的患者。进行了三次访视：基线访视、6个月访视和12个月访视。依从性通过电子监测器（MEMS）进行测量，该监测器在药物容器盖子中的微芯片以数字记录的形式自动控制其开启，并记录开启的时间和日期。我们计算了平均依从率（CP）、总体依从性和每日依从性。我们认为当CP为80%-100%时为依从。
370例患者完成了研究（平均年龄75.19岁，标准差：7.5岁）。6个月和12个月后的总体依从性分别为84.1%（CI = 79.21-88.99%）和80.3%（CI = 74.98-85.62%）。6个月和12个月时的每日依从性分别为83.5%（CI = 78.53-88.57%）和80%（CI = 74.65-85.35%）。观察到6个月和12个月之间CP存在显著差异。6个月后总体CP为90.77%，研究结束时为89.65%。6个月和12个月时的每日CP分别为90.14%和87.66%。6个月和12个月之间CP存在显著差异。不依从与更多的合并疾病、所服用药物的数量和体重相关。
利伐沙班的依从率较高。检测到当前医疗实践中与不依从相关的需要调整的变量概况。
